Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid ...

Cash and cash equivalents totaled €119.0 million as of September 30, 2025€39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following ...

FSSAI orders removal of non-compliant drinks falsely labelled as “ORS”, targeting deceptive marketing and protecting ...

The emerging prevalence of digitalization is a key topic for manufacturers handling excipients. Digital transformation and data integrity protocols are crucial strategies for optimizing drug ...

Researchers from Johns Hopkins University have developed an oral treatment that could soon be used to destroy cancer cells ...

The approval puts Lunsumio on the same footing as Epkinly (epcoritamab) in FL – a form of non-Hodgkin lymphoma (NHL) – as ...

In particular, Konagurthu says, AI/ML can help sift through a field of drug candidates in which the percentage that are ...

Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and ...

Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy ...

Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable ...

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...